Protein-Protein Interactions Part I icon  

Tenth Annual

Protein-Protein Interactions, Part 1

Targeting PPIs for Therapeutic Interventions

April 24-25, 2017


Protein-Protein Interactions (PPIs) are the basis of many important cellular processes and being able to disrupt or stabilize PPIs offers innovative routes for new therapeutics. However, PPIs are difficult to screen against due to their lack of easily assayable output (no enzymatic activity to measure). Indeed, some pharmaceutical industry companies remain apprehensive of full-fledged drug discovery campaigns in this direction. Yet progress is being made, in large part thanks to advances in biophysical techniques, which enable detection and measurement of interactions between molecules. Rational design of PPI inhibitors based on protein structures and computational analysis has also spurred progress, but figuring out which sites to target in these ‘new’ types of targets has posed a challenge. This meeting gathers leading medicinal chemists, biophysical chemists, structural biologists and discovery biologists in the drug discovery industry to share their successes and failures with the goal of making the pathway for PPI-targeted compounds to therapeutic success less murky. Are there ‘rules’ or commonalities to be gleaned from shared experiences?

Topics will include, but are not limited to:

  • Case studies of compounds in development (XIAP-SMAC, Keap1-NRF2, and more)
  • New targets from PPI-rich processes (ubiquitin pathway, apoptosis, DNA repair, infectious diseases)
  • Retrospective ‘success’ and ‘failure’ stories (BCL2 and partners, p53-MDMX)
  • Biophysical tools for PPIs (rational drug-design/structure-based approaches, fragment-based methods, NMR, SPR and other biosensors, probing allosteric changes, covalent inhibitors)
  • Updates on PPI databases and networks

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 7, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

We hope you can join us for this day-and-a-half conference (one of four parallel tracks) that is in the first half of our larger Drug Discovery Chemistry event. Attending this meeting enables you to also hop to concurrent meeting tracks to hear other presentations of interest.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6252
Email: ashah@healthtech.com

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com